Recently, Oregon’s two senators urged the chief of the U.S. FDA (Food and Drug Administration) to revise federal regulations to allow the interstate business of food products including an important non-psychoactive component of cannabis. The plea by Senator Ron Wyden and Senator Jeff Merkley came following Congress legalized the manufacture and sale of hemp derivatives and industrial hemp, including CBD (cannabidiol). Wyden and Merkley had been after a hemp stipulation that Congress approved and was integrated into the 2018 Farm Bill.
But, subsequent to President Donald Trump inked the bill in December, Scott Gottlieb—the FDA’s Commissioner—restated his bureau’s attitude that CBD is a drug component and therefore it is illegal to add in food and health products without agency’s sanction. The FDA has forwarded warning letters to several companies making health alleges for CBD. In a letter to Gottlieb, the senators urged the FDA to revise “outdated rules” that forbid food products including CBD from getting sold in state lines. They stated that “farmers in Oregon and countrywide are self-confident to make real economic profits for their communities if these rules are updated.” They further added it was Congress’ intention in the bill to make sure consumers and producers have right of entry to hemp-derived products, counting those that hold CBD.
Lately, the FDA was also in news as it approved scalpel-free treatment for neurodegenerative disease tremor. The U.S. FDA has approved a scalpel-free and novel treatment for tremor in patients who are having medication-resistant Parkinson’s disease. The process—which is called focused ultrasound—permits doctors to execute brain surgery devoid of cutting into the skull. It was found effective and safe for lowering medication-resistant Parkinson’s tremor into clinical tests conducted by Jeff Elias, Neurosurgeon at the UVA’s (University of Virginia) School of Medicine.